Date | Time | Source | Announcement |
---|---|---|---|
02 Oct 2006 | 07:00 AM | Gene Therapy for Blindness | |
25 Sep 2006 | 02:32 PM | Holding(s) in Company | |
20 Sep 2006 | 10:08 AM | Holding(s) in Company | |
07 Sep 2006 | 10:54 AM | Interest in Share Options | |
05 Sep 2006 | 07:01 AM | SWOG in phase 2 Trovax trial | |
05 Sep 2006 | 07:00 AM | Interim Results | |
21 Aug 2006 | 07:00 AM | Trovax at Cancer Conference | |
03 Aug 2006 | 04:00 PM | Holding(s) in Company | |
02 Aug 2006 | 07:00 AM | Notice of Interim Results | |
31 Jul 2006 | 07:00 AM | Trovax Update & Clarification | |
18 Jul 2006 | 04:09 PM | Holding(s) in Company | |
06 Jul 2006 | 04:31 PM | Holding(s) in Company | |
05 Jul 2006 | 04:54 PM | Director/PDMR Shareholding | |
26 Jun 2006 | 11:43 AM | Holding(s) in Company | |
26 Jun 2006 | 07:00 AM | Prosavin Patent | |
21 Jun 2006 | 07:00 AM | Piper Jaffray Health Care | |
14 Jun 2006 | 07:00 AM | SUIT AGAINST OPEN BIOSYSTEMS | |
12 Jun 2006 | 04:00 PM | Holding(s) in Company | |
07 Jun 2006 | 07:00 AM | Phase II results - TROVAX | |
23 May 2006 | 07:00 AM | Phase II Trial Trovax | |
22 May 2006 | 04:30 PM | Holding(s) in Company | |
18 May 2006 | 07:00 AM | Blocklisting Interim Review | |
16 May 2006 | 08:51 AM | Director/PDMR Shareholding | |
12 May 2006 | 07:00 AM | Agreement with FDA | |
04 May 2006 | 11:53 AM | Annual General Meeting 06 | |
02 May 2006 | 07:01 AM | RETINOSTAT | |
20 Apr 2006 | 05:38 PM | Holding(s) in Company | |
11 Apr 2006 | 04:26 PM | Annual Report and Accounts | |
11 Apr 2006 | 08:21 AM | Annual Information Update | |
06 Apr 2006 | 01:23 PM | Holding(s) in Company | |
30 Mar 2006 | 07:01 AM | Clinical Trial Results | |
24 Mar 2006 | 12:40 PM | Holding(s) in Company | |
23 Mar 2006 | 11:03 AM | Director/PDMR Shareholding | |
16 Mar 2006 | 04:04 PM | Director/PDMR Shareholding | |
14 Mar 2006 | 07:00 AM | Preliminary Results | |
10 Mar 2006 | 07:00 AM | VIRxSYS Corporation Licence | |
23 Feb 2006 | 07:00 AM | Notice of Results | |
03 Feb 2006 | 09:48 AM | Board Appointment | |
26 Jan 2006 | 09:46 AM | Holding(s) in Company | |
24 Jan 2006 | 08:44 AM | Holding(s) in Company | |
18 Jan 2006 | 04:13 PM | Viragen Milestone | |
04 Jan 2006 | 10:12 AM | Holding(s) in Company | |
20 Dec 2005 | 04:42 PM | Holding(s) in Company | |
19 Dec 2005 | 05:10 PM | Holding in Company Correction | |
19 Dec 2005 | 04:55 PM | Holding(s) in Company | |
19 Dec 2005 | 11:07 AM | Holding(s) in Company | |
16 Dec 2005 | 01:45 PM | Director/PDMR S/hldg-Amend | |
16 Dec 2005 | 08:23 AM | Director/PDMR Shareholding | |
15 Dec 2005 | 09:00 AM | Director/PDMR Shareholding | |
12 Dec 2005 | 12:34 PM | Holding(s) in Company |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.